Zobrazeno 1 - 10
of 195
pro vyhledávání: '"Keessen M"'
Autor:
Vaishampayan UN; University of Michigan Ann Arbor, MI, USA., Keessen M; Modra Pharmaceuticals B.V., Amsterdam, Netherlands. Electronic address: mariannekeessen@gmail.com., Dreicer R; University of Virginia, Charlottesville, VA, USA., Heath EI; Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA., Buchler T; Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Prague, Czech Republic., Árkosy PF; Debrecen Institute of Oncology, Debrecen, Hungary., Csöszi T; Hetenyi G Korhaz, Szolnok, Hungary., Wiechno P; Klinika Nowotworów Układu Moczowego Centrum Onkologii, Warsaw, Poland., Kopyltsov E; State Institution of Healthcare, Omsk, Russian Federation., Orlov SV; Pavlov First St. Petersburg State Medical University, Saint Petersburg, Russian Federation., Plekhanov A; Clinic 'Andros' LLC, Saint Petersburg, Russian Federation., Smagina M; Leningrad Regional Oncology Dispensary, Saint Petersburg, Russian Federation., Varlamov S; Altai Regional Cancer Center, Barnaul, Russian Federation., Shore ND; Carolina Urologic Research Center, Myrtle Beach, SC, USA.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2024 May; Vol. 202, pp. 114007. Date of Electronic Publication: 2024 Mar 11.
Autor:
Vermunt MAC; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands. m.vermunt@nki.nl., de Weger VA; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands., Janssen JM; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands., Lopez-Yurda MI; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Keessen M; Modra Pharmaceuticals BV, Amsterdam, The Netherlands., Thijssen B; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands., Rosing H; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands., Huitema ADR; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands., Beijnen JH; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066CX, Amsterdam, The Netherlands.; Modra Pharmaceuticals BV, Amsterdam, The Netherlands.; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Marchetti S; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Publikováno v:
Drugs in R&D [Drugs R D] 2021 Mar; Vol. 21 (1), pp. 103-111. Date of Electronic Publication: 2021 Jan 19.
Autor:
Vermunt MAC; Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Robbrecht DGJ; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Devriese LA; Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands., Janssen JM; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Thijssen B; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Keessen M; Modra Pharmaceuticals B.V., Amsterdam, The Netherlands., van Eijk M; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Kessels R; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Eskens FALM; Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Beijnen JH; Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Modra Pharmaceuticals B.V., Amsterdam, The Netherlands.; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Mehra N; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Bergman AM; Department of Medical Oncology and Oncogenomics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Publikováno v:
Cancer reports (Hoboken, N.J.) [Cancer Rep (Hoboken)] 2021 Aug; Vol. 4 (4), pp. e1367. Date of Electronic Publication: 2021 Mar 12.
Autor:
Wang, Hao1 (AUTHOR), Gong, Feirong1 (AUTHOR), Liu, Jiajie1 (AUTHOR) qxzhuang@ecust.edu.cn, Xiang, Lanlan1 (AUTHOR), Hu, Yanfen1 (AUTHOR), Che, Wenchen1 (AUTHOR), Li, Ran1 (AUTHOR), Yang, Sisi1 (AUTHOR), Zhuang, Qixin1 (AUTHOR), Teng, Xin1 (AUTHOR) tengxin@ecust.edu.cn
Publikováno v:
Bioengineering (Basel). Nov2024, Vol. 11 Issue 11, p1078. 15p.
Autor:
Pereira, Mariana1,2,3 (AUTHOR), Vale, Nuno1,2,4 (AUTHOR) nunovale@med.up.pt
Publikováno v:
Current Oncology. Oct2024, Vol. 31 Issue 10, p6032-6049. 18p.
Autor:
Van Der Noll, R., Smit, W. M., Wymenga, A. N M, Boss, D. S., Grob, M., Huitema, A. D R, Rosing, H., Tibben, M. M., Keessen, M., Rehorst, H., Beijnen, J. H., Schellens, J. H M
Summary: Background Lapatinib has proven efficacy as monotherapy and in combination with capecitabine in patients with metastatic breast cancer (MBC) overexpressing HER2 and/or EGFR. Gemcitabine also has anti-tumor activity in MBC and a favourable to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od_______101::56435cba32ce4fd3d3cd828b90244eae
https://dspace.library.uu.nl/handle/1874/327610
https://dspace.library.uu.nl/handle/1874/327610
Autor:
Macedo, Luiza de Oliveira1 (AUTHOR), Masiero, Jéssica Fagionato1 (AUTHOR), Bou-Chacra, Nádia Araci1 (AUTHOR) chacra@usp.br
Publikováno v:
Pharmaceutics. Sep2024, Vol. 16 Issue 9, p1141. 21p.
Autor:
Perez, Aleymi M.1,2 (AUTHOR) aperez31980@med.lecom.edu, Haberland, Nicole I.1,3 (AUTHOR) ni315488@ucf.edu, Miteva, Mariya1 (AUTHOR) mmiteva@med.miami.edu, Wikramanayake, Tongyu C.1,4 (AUTHOR) tcao@med.miami.edu
Publikováno v:
Current Oncology. Sep2024, Vol. 31 Issue 9, p5709-5721. 13p.
Autor:
Arbitman, Leah1 (AUTHOR) bkim101@binghamton.edu, Chen, Shirley1 (AUTHOR), Kim, Brian1 (AUTHOR), Lee, Melinda1 (AUTHOR), Zou, Peng2 (AUTHOR), Doughty, Bennett1 (AUTHOR), Li, Yanyan1 (AUTHOR), Zhang, Tao1 (AUTHOR) zhangt@binghamton.edu
Publikováno v:
Pharmaceutics. Jul2024, Vol. 16 Issue 7, p847. 16p.
Autor:
de Weger VA; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands., Stuurman FE; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Koolen SLW; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Moes JJ; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, the Netherlands., Hendrikx JJMA; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, the Netherlands., Sawicki E; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, the Netherlands.; Modra Pharmaceuticals BV, Amsterdam, the Netherlands., Thijssen B; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, the Netherlands., Keessen M; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Modra Pharmaceuticals BV, Amsterdam, the Netherlands., Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, the Netherlands., Mergui-Roelvink M; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, the Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht, the Netherlands., Nuijen B; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, the Netherlands., Beijnen JH; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute and MC Slotervaart, Amsterdam, the Netherlands.; Modra Pharmaceuticals BV, Amsterdam, the Netherlands.; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Schellens JHM; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.; Modra Pharmaceuticals BV, Amsterdam, the Netherlands.; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, the Netherlands., Marchetti S; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. s.marchetti@nki.nl.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Sep 15; Vol. 25 (18), pp. 5466-5474. Date of Electronic Publication: 2019 Jun 19.